Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Role of HINT1 in Neuropathic Pain: Insights Provided by Studies on the Spared Nerve Injury Model and HINT1 Inhibition
Pain
S24 - Pain and Palliative Care: Targeted Therapy in Chronic Pain Disorders (4:08 PM-4:16 PM)
002

Background: Transmission of pain in spinal cord to brain requires N-methyl-D-aspartate receptor (NMDAR) activity to transmit glutamatergic signaling between neurons. NMDAR activity is decreased due to opiates activating the mu-opioid receptor (MOR) in the short term. In the long term, a tolerance to this effect develops, which is a major contributor to dose escalation and subsequently the abuse of opiates. Cross-talk between MOR and NMDAR is mediated by HINT1. HINT1 has not been studied in neuropathic pain states, a prolonged state of pain in which several mechanisms lead to continuous activity of NMDAR and thus the perception of pain. Depending on the role of HINT1 in neuropathic pain, HINT1 may be a promising target for alternatives to opiates in the treatment of pain. 

Objective: Our goal was to determine expression levels of histidine triad nucleotide-binding protein 1 (HINT1) protein in dorsal root ganglia (DRG) of mice induced to exhibit chronic neuropathic pain. We also explored the change in behavioral manifestation of chronic neuropathic pain when these mice are injected intrathecally with HINT1 inhibitors.

Methods: Immunohistochemistry, spared nerve injury, intrathecal injection, confocal imaging, Von Frey mechanical hypersensitivity threshold, rotarod

Results/Conclusions: While further testing is required, initial results indicate no significant increase of HINT1 expression in lumbar segment 3 DRG ipsilateral to nerve injury; this segment innervates the area of induced chronic pain. We also observed a significant decrease in the behavioral manifestation of hypersensitivity when mice were intrathecally injected with HINT1 inhibitors.

These data further solidify the logic of inhibiting HINT1 as a potential therapy for chronic pain. This information serves as a useful stepping stone to develop an alternative therapy to opiates for use in chronic pain.
Authors/Disclosures
Rishi Sharma, MD
PRESENTER
Mr. Sharma has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file